BioProcess International Magazine

2 weeks ago | bioprocessintl.com | James Choi |Josh Abbott |Shreeyashi Ojha |Dan Stanton

Planning for commercial biologic manufacturing is challenging, not least because it requires considerable time, investment, and economic risk. As global demand for biopharmaceuticals climbs, drug companies will need to be resourceful to ensure that their products will be manufactured at sufficient volumes and in the desired markets. This eBook places bioproduction capacity in the spotlight, highlighting options that biologics developers can leverage as they seek to expand their global reach.

2 weeks ago | bioprocessintl.com | Shreeyashi Ojha

Piramal facility expansionstock.adobe.comAt its Lexington, Kentucky site – specializing in sterile compounding, liquid filling, and lyophilization for injectable drugs – the Indian CDMO is adding 24,000 square-feet of manufacturing space and a new lab. The expansion includes a new filling line, two commercial-scale lyophilizers, an external vial washer, and a special capping machine. The facility is expected to open by late 2027.

3 weeks ago | bioprocessintl.com | Dan Stanton

Roche is building a $700m fill/finish plant in Holly Springs, North CarolinaDepositPhotos/ellandarLast month, Swiss biopharma giant Roche announced plans to invest $50 billion across its US network, both in pharmaceutical and diagnostics R&D and manufacturing. Among the projects, the firm laid out plans to build a gene therapy facility in Pennsylvania and to expand/upgrade manufacturing and distribution capabilities in Kentucky, Indiana, New Jersey, Oregon, and California.

3 weeks ago | bioprocessintl.com | Dan Stanton |Josh Abbott

Imunon looks to DNA vaccine tech to support ovarian cancer immunotherapyDepositPhotos/drecunThe New Jersey-based biotech is developing non-viral DNA technology for various modalities. Its lead candidate is IMNN-001, an immunotherapy for ovarian cancer, based on the firm’s TheraPlas platform.

3 weeks ago | bioprocessintl.com | Shreeyashi Ojha

Swiss firm NewBiologix (NBX) has licensed its Xcell-Eng-HEK293 cell line to contract development and manufacturing organization (CDMO) ReciBioPharm for development and production of adeno-associated virus (AAV) therapies for clinical trials. According to the cell and gene therapy (CGT)-focused NBX, its licensed cell line boosts recombinant AAVs manufacturing by combining multidimensional digital polymerase chain reaction (PCR) with third-generation sequencing.